Found: 178
Select item for more details and to access through your institution.
Real-world outcome of patients with extensively pretreated multiple myeloma who were treated with selinexor and dexamethasone: a Korean multicenter retrospective analysis.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 7, p. 2365, doi. 10.1007/s00277-024-05615-0
- By:
- Publication type:
- Article
Nation-Wide Retrospective Analysis of Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma: A Study from Korean Multiple Myeloma Working Party (KMM1913).
- Published in:
- Cancer Research & Treatment, 2024, v. 56, n. 3, p. 956, doi. 10.4143/crt.2024.074
- By:
- Publication type:
- Article
The establishment of a multiple myeloma clinical registry in the Asia–Pacific region: The Asia–Pacific Myeloma and Related Diseases Registry (APAC MRDR).
- Published in:
- BMC Medical Research Methodology, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12874-024-02227-0
- By:
- Publication type:
- Article
Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-57295-5
- By:
- Publication type:
- Article
Outcome of Multiple Myeloma Patients With Hepatitis B Surface Antigen: Korean Multiple Myeloma Working Party 2103 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 2, p. e50, doi. 10.1016/j.clml.2023.10.004
- By:
- Publication type:
- Article
Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1275076
- By:
- Publication type:
- Article
Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomidebased regimens (KMM170).
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1209110
- By:
- Publication type:
- Article
Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015).
- Published in:
- Annals of Hematology, 2023, v. 102, n. 8, p. 2233, doi. 10.1007/s00277-023-05308-0
- By:
- Publication type:
- Article
Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia.
- Published in:
- Cancer Research & Treatment, 2023, v. 55, n. 3, p. 1011, doi. 10.4143/crt.2022.1407
- By:
- Publication type:
- Article
Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 6, p. 446, doi. 10.1016/j.clml.2023.02.009
- By:
- Publication type:
- Article
Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1233, doi. 10.1007/s00262-022-03322-1
- By:
- Publication type:
- Article
Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma.
- Published in:
- International Journal of Hematology, 2023, v. 117, n. 2, p. 225, doi. 10.1007/s12185-022-03479-6
- By:
- Publication type:
- Article
Natural killer cell therapy potentially enhances the antitumor effects of bevacizumab plus irinotecan in a glioblastoma mouse model.
- Published in:
- Frontiers in Immunology, 2023, v. 13, p. 01, doi. 10.3389/fimmu.2022.1009484
- By:
- Publication type:
- Article
Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00755-w
- By:
- Publication type:
- Article
Next‐generation sequencing‐based analysis to assess the pattern of relapse in patients with Philadelphia‐positive acute lymphoblastic leukemia.
- Published in:
- EJHaem, 2022, v. 3, n. 4, p. 1145, doi. 10.1002/jha2.514
- By:
- Publication type:
- Article
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01374-5
- By:
- Publication type:
- Article
Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study).
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.959949
- By:
- Publication type:
- Article
Correction to: Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805).
- Published in:
- International Journal of Hematology, 2022, v. 116, n. 1, p. 110, doi. 10.1007/s12185-022-03332-w
- By:
- Publication type:
- Article
A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.879452
- By:
- Publication type:
- Article
Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 6, p. 1217, doi. 10.1007/s00277-022-04776-0
- By:
- Publication type:
- Article
Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 613, doi. 10.1007/s00262-021-02982-9
- By:
- Publication type:
- Article
Clinical trial participation improves survival outcomes by increasing availability of new therapeutic agents in multiple myeloma.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 4, p. 1117, doi. 10.1111/bjh.17898
- By:
- Publication type:
- Article
Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On 18F-FDG PET/CT at Baseline.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 2, p. 113, doi. 10.1016/j.clml.2021.08.012
- By:
- Publication type:
- Article
Prevalence and Risk Factors for Adrenal Insufficiency in Patients with Multiple Myeloma Receiving Long-Term Chemotherapy including Corticosteroids: A Retrospective Cohort Study.
- Published in:
- BioMed Research International, 2021, p. 1, doi. 10.1155/2021/2330417
- By:
- Publication type:
- Article
Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-02433-6
- By:
- Publication type:
- Article
P-006: Expanded natural killer cells with daratumumab, lenalidomide and dexamethasone combination potentiates antimyeloma activity in a myeloma xenograft model.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S42, doi. 10.1016/S2152-2650(21)02140-6
- By:
- Publication type:
- Article
P-013: Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S46, doi. 10.1016/S2152-2650(21)02147-9
- By:
- Publication type:
- Article
P-118: Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S99, doi. 10.1016/S2152-2650(21)02245-X
- By:
- Publication type:
- Article
P-199: Real-world toxicity and efficacy of ixazomib, lenalidomide and dexamethasone in Asian RRMM patients supported by the patient assistance program.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S147, doi. 10.1016/S2152-2650(21)02326-0
- By:
- Publication type:
- Article
P-200: Pomalidomide-based chemotherapy in plasmacytoma at relapse.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S148, doi. 10.1016/S2152-2650(21)02327-2
- By:
- Publication type:
- Article
Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial.
- Published in:
- Annals of Hematology, 2021, v. 100, n. 8, p. 2051, doi. 10.1007/s00277-021-04407-0
- By:
- Publication type:
- Article
Prognostic impact of <sup>18</sup>F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial‐unfit patients and subsequent therapy.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 1, p. 101, doi. 10.1111/bjh.17071
- By:
- Publication type:
- Article
HMGB1 orchestrates STING-mediated senescence via TRIM30α modulation in cancer cells.
- Published in:
- Cell Death Discovery, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41420-021-00409-z
- By:
- Publication type:
- Article
Pilot Study: Quantitative Photoacoustic Evaluation of Peripheral Vascular Dynamics Induced by Carfilzomib In Vivo.
- Published in:
- Sensors (14248220), 2021, v. 21, n. 3, p. 836, doi. 10.3390/s21030836
- By:
- Publication type:
- Article
Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 1, p. 31, doi. 10.1007/s00262-020-02654-0
- By:
- Publication type:
- Article
Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone.
- Published in:
- International Journal of Hematology, 2021, v. 113, n. 1, p. 81, doi. 10.1007/s12185-020-02988-6
- By:
- Publication type:
- Article
RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41598-020-76933-2
- By:
- Publication type:
- Article
Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk.
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. N.PAG, doi. 10.1186/s13045-020-00948-5
- By:
- Publication type:
- Article
Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma.
- Published in:
- In Vivo, 2020, v. 34, n. 4, p. 2127, doi. 10.21873/invivo.12018
- By:
- Publication type:
- Article
Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Peptide Vaccine Combined Adjuvants Modulate Anti-tumor Effects of Radiation in Glioblastoma Mouse Model.
- Published in:
- Frontiers in Immunology, 2020, p. 1, doi. 10.3389/fimmu.2020.01165
- By:
- Publication type:
- Article
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 4, p. 413, doi. 10.1002/ajh.25726
- By:
- Publication type:
- Article
The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study).
- Published in:
- 2020
- By:
- Publication type:
- journal article
Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Prognostic significance of FDG-PET/CT in determining upfront autologous stem cell transplantation for the treatment of peripheral T cell lymphomas.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
- Published in:
- BMC Veterinary Research, 2019, v. 15, n. 1, p. N.PAG, doi. 10.1186/s12917-019-2068-5
- By:
- Publication type:
- Article